NKGen Biotech, Inc. Common Stock
NKGN
NKGN was delisted on the 4th of March, 2025.
9 hedge funds and large institutions have $13.7M invested in NKGen Biotech, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
31% less funds holding
Funds holding: 13 → 9 (-4)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
71% less capital invested
Capital invested by funds: $47.9M → $13.7M (-$34.2M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$3.49M |
| 2 |
UOC
University of Chicago
Chicago,
Illinois
|
+$1.77M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$148K |
| 4 |
Millennium Management
New York
|
+$59.4K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$50.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$6.01M |
| 2 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$3.91M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$3.61M |
| 4 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$2.91M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.58M |
NKGN Hedge Fund Activity: Q4 2023 in Review
9 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q4 2023, worth a combined $13.7M — down 71% from $47.9M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NKGN and 7 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Polar Asset Management Partners, opening a new position worth an estimated $3.49M. The largest seller was Rivernorth Capital Management, exiting entirely with an estimated $6.01M sold.
- 9 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q4 2023, down from 13 in Q3 2023.
- Funds reported $13.7M of NKGen Biotech, Inc. Common Stock stock for Q4 2023, down 71% quarter-over-quarter.
- 7 funds opened new NKGen Biotech, Inc. Common Stock positions in Q4 2023 and 11 closed out, a net change of -4 holders.
- The largest NKGen Biotech, Inc. Common Stock buyer in Q4 2023 was Polar Asset Management Partners, an estimated $3.49M added.
- The largest NKGen Biotech, Inc. Common Stock seller in Q4 2023 was Rivernorth Capital Management, an estimated $6.01M sold.
Based on aggregated 13F filings for Q4 2023.